Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Tetra Bio Pharma Inc
(TSX:
TBP
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Mar 6, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
0.0100 (5,000)
Ask (Size)
0.0250 (50)
Prev. Close
0.0250
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003
March 03, 2023
The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral...
Via
TheNewswire.com
Exposures
COVID-19
Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements and Related Management's Discussion and Analysis
March 01, 2023
MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and...
Via
TheNewswire.com
Performance
More News
Read More
The Power Play by The Market Herald Releases New Interviews with Group Eleven, iMining, Gamelancer, Cassiar Gold, ApartmentLove, Tetra Bio-Pharma and Sitka Gold Discussing Their Latest News
November 30, 2022
Via
ACCESSWIRE
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
July 12, 2022
From
Akanda Corp. and Tetra Bio-Pharma
Via
Business Wire
Keynotes, Educational Panels and 70 Companies to Present at the SNN Network Canada Virtual Event on December 7-9, 2021
December 06, 2021
From
Stock News Now
Via
AccessWire
Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials Of QIXLEEF For Cancer Pain
November 29, 2021
Via
Benzinga
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
June 02, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain
May 11, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial
May 06, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
May 05, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Tetra Bio-Pharma Re-activates Veterinary Clinical Study in Companion Animals
May 04, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
COVID-19
Cannabis
Intellectual Property
Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada
May 03, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
April 28, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
April 23, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
April 15, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada
April 14, 2021
From
Tetra Bio-Pharma
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.